ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

NVUS Novus Therapeutics Inc

14.60
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novus Therapeutics Inc NASDAQ:NVUS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 14.60 14.65 21.00 0 01:00:00

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Tokai Pharmaceuticals, Inc. - TKAI

10/04/2017 5:56pm

PR Newswire (US)


Novus Therapeutics (NASDAQ:NVUS)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Novus Therapeutics Charts.

NEW YORK, April 10, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, is investigating Tokai Pharmaceuticals, Inc. ("Tokai" or the "Company") (NasdaqGM: TKAI) and its Board of Directors for potential securities laws violations and/or breaches of fiduciary duties in connection with the share purchase agreement with Otic Pharma, Ltd. ("Otic")(the "Otic Transaction").  As a result of the Otic Transaction, Otic will become a wholly owned subsidiary of Tokai and the they will own approximately 60% of the Tokai common stock.

Monteverde & Associates PC

Click here for more information: http://monteverdelaw.com/investigations/m-a/.  It is free and there is no cost or obligation to you.

The investigation focuses on whether Tokai and/or its Board of Directors violated federal securities laws and/or breached their fiduciary duties to the Company's stockholders by 1) failing to properly value the Otic Transaction and 2) failing to disclose all material information in connection with the Otic Transaction.  

Monteverde & Associates PC is a boutique class action securities and consumer litigation law firm that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing.  Monteverde & Associates PC lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct.

If you own common stock in Tokai and wish to obtain additional information and protect your investments free of charge, please visit us at www.monteverdelaw.com/investigations/m-a/  or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com 
Tel: (212) 971-1341

Attorney Advertising. (C) 2017 Monteverde & Associates PC.  The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter. 

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-monteverde--associates-pc-announces-an-investigation-of-tokai-pharmaceuticals-inc---tkai-300437264.html

SOURCE Monteverde & Associates PC

Copyright 2017 PR Newswire

1 Year Novus Therapeutics Chart

1 Year Novus Therapeutics Chart

1 Month Novus Therapeutics Chart

1 Month Novus Therapeutics Chart

Your Recent History

Delayed Upgrade Clock